Fwd: When Ozempic stops working (and what 10% of users already know)

Snippet

Body

TJ
Begin forwarded message:

 From: Seed Oil Scout <newsletter@seedoilscout.com>
 Date: March 17, 2026 at 1:36:08 PM EDT
 To: tjphuhs@gmail.com
 Subject: When Ozempic stops working (and what 10% of users already know)

 

 96
 The non-responder problem, the plateau trap, and the side effects pharma buries in the fine print.  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­
 When Ozempic Stops Working: The 1-in-10 Problem Nobody Talks About
 PRIMA just leveled up. Now packed with 21g of grass-fed protein , it’s the same ancestral bar you trust — only better.
Better texture. Better taste. More of what actually fuels you.


 Use SOS15 for 15% off on your first purchase


GLP-1 drugs have been called miracle treatments. But roughly 10% of users are "non-responders," and a growing number of long-term users are hitting plateaus. What happens when the magic wears off?

  
 The Non-Responder Problem
 In the STEP 1 trial , about 1 in 10 semaglutide users failed to lose even 5% of body weight, the minimum threshold considered clinically meaningful. In the SURMOUNT-2 trial for tirzepatide, 17-21% of participants didn't hit that 5% mark.




 Why? Variants in the GLP-1 receptor gene affect how strongly the drug signals satiety. Gut microbiome composition also influences response. And if your metabolism is already adapted to caloric restriction from years of yo-yo dieting, these drugs have less runway to work with.


   Plateau Nation

 Even among responders, the ride doesn't last forever. The STEP 1 extension study found that after stopping semaglutide, participants regained two-thirds of their lost weight within one year. Cardiometabolic improvements reverted toward baseline too.




 But it's not just about stopping. Users 12+ months in report stalls even while still on the drug. The response: dose escalation. Higher dose, more side effects, diminishing returns. Weight loss curves flatten between months 12 and 18. Your body adapts, the same way it adapts to every other weight-loss intervention ever tried.

  
The Side Effects Nobody Wants to Talk About GLP-1 drugs aren't just nausea and constipation. The side effect profile gets darker the longer you look:


 Muscle loss : Up to 40% of weight lost on semaglutide is lean mass , not fat. That's muscle, bone density, and metabolic tissue you need to age well.
 Gastroparesis : The FDA added a warning about delayed gastric emptying so severe it can cause bowel obstruction. Some users report symptoms persisting after stopping the drug.
 Gallbladder disease : Clinical trials documented cholelithiasis (gallstones) at rates 2-3x higher than placebo. Rapid weight loss plus altered bile metabolism is a known recipe.
 Pancreatitis : The FDA label for semaglutide carries a warning for acute pancreatitis. Rates are low but the condition is serious.
 Thyroid tumors : All GLP-1 drugs carry a boxed warning about thyroid C-cell tumors based on animal studies. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma.
 "Ozempic face" : The gaunt, aged facial appearance from rapid fat and muscle loss. It's cosmetic, but it signals something deeper: your body is cannibalizing tissue, not just fat.   Retatrutide and the Heart Rate Problem
 Retatrutide is Eli Lilly's triple agonist (GIP/GLP-1/glucagon). Early results: up to 24.2% weight loss at 48 weeks per the NEJM Phase 2 trial. But buried in the data: dose-dependent increases in heart rate peaking at 24 weeks.



 The glucagon receptor component is the likely culprit. At the 12mg dose, heart rate elevations were clinically notable. Users report resting heart rates climbing 10-20 bpm. For a drug class prescribed to people already at elevated cardiovascular risk, that should raise questions, not just heart rates.


   What Non-Responders Discover Here's the irony. When GLP-1 drugs stop working (or never start), patients are forced back to the basics that actually build metabolic health:

 Protein : 1g per pound of ideal body weight. Protects lean mass, drives satiety without a prescription.
 Sleep : Poor sleep increases ghrelin and tanks leptin sensitivity . No drug fixes that.
 Real fats : Butter, tallow, olive oil. The kind that signal fullness and don't require a weekly injection. (And yes, avoiding seed oils.) The metabolic foundation that drugs can't replace is the same one it's always been: eat real food, move, sleep.

  
 Bottom Line About 10% of GLP-1 users are non-responders, and many more hit plateaus after 12 months.
 After stopping semaglutide, people regain two-thirds of lost weight within a year. Side effects include significant muscle loss, gallbladder disease, gastroparesis, pancreatitis risk, and thyroid concerns. Retatrutide shows dose-dependent heart rate increases that deserve more scrutiny.
 When the drug stops working, the answer is the same as it always was: protein, sleep, real food. GLP-1 drugs work for most people. But they're not a permanent fix for a broken food system.

   PRIMA JUST GOT STRONGER.

 21 grams of grass-fed protein. Same real whole-food ingredients. Better texture. Better taste. The ancestral protein bar you already trusted — now with more of what you asked for. No seed oils, ever. No isolates. No syrups. No shortcuts. Just real food, done right.


 [ SHOP THE NEW FORMULA ]

   Did you like this newsletter?

 Loved it! ❤️
 It could be better. 👎


 Seed Oil Scout subscriptions keep this newsletter afloat! Get unlimited access to clean dining globally for a deep discount of $19.99 when you join here









 © 2025 Seed Oil Scout’s Newsletter
108 W 13th Street

 Wilmington, DE 19801,
United States of America





 unsubscribe